Eric Green, Trace Neuroscience CEO
Maze's ALS spinout Trace Neuroscience raises $101M for ALS and neuro work
Trace Neuroscience, a startup spun out of Maze Therapeutics’ pipeline, broke cover Tuesday morning with $101 million in funding to develop treatments for amyotrophic lateral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.